T1	p 191 238	herpes zoster ( HZ ) and postherpetic neuralgia
T2	p 262 297	individuals > or =60 years of age .
T3	p 473 568	in subjects > or =50 years of age . Subjects with a negative history for HZ were randomized 1:1
T4	p 639 660	1:2 by age ( 50 to 59
T5	i 98 129	refrigerator-stable formulation
T6	i 133 143	Zostavax .
T7	i 148 164	vaccine Zostavax
T8	i 357 414	refrigerator-stable formulation ( Zostavax refrigerated )
T9	i 433 472	current formulation ( Zostavax frozen )
T10	i 599 612	formulation .
T11	i 741 757	Varicella-zoster
T12	i 837 850	immunosorbent
T13	i 1905 1913	Zostavax
T14	o 690 696	Safety
T15	o 739 790	. Varicella-zoster virus ( VZV ) antibody responses
T16	o 810 836	glycoprotein enzyme-linked
T17	o 902 941	VZV antibody geometric mean titer ( GMT
T18	o 959 997	VZV antibody geometric mean rise ( GMR
T19	o 1017 1089	and the incidence of vaccine-related serious adverse experiences ( AEs )
T20	o 1186 1190	GMTs
T21	o 1249 1316	estimated GMT ratio ( refrigerated formulation/frozen formulation )
T22	o 1424 1451	vaccine-related serious AEs
T23	o 1492 1507	safety profiles
T24	o 1557 1590	frequencies of injection-site AEs
T25	o 1744 1759	of systemic AEs
T26	o 1932 1938	safety